Passage Bio Analyst Ratings
Passage Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 977.84% | Chardan Capital | $11 → $9 | Maintains | Buy |
| 05/12/2023 | 977.84% | Raymond James | $10 → $9 | Maintains | Outperform |
| 12/15/2022 | 1217.37% | Chardan Capital | $18 → $11 | Maintains | Buy |
| 11/11/2022 | 1217.37% | Guggenheim | $13 → $11 | Maintains | Buy |
| 11/11/2022 | 498.8% | Citigroup | $7 → $5 | Maintains | Buy |
| 11/08/2022 | 858.08% | Canaccord Genuity | → $8 | Initiates Coverage On | → Buy |
| 05/17/2022 | 1097.6% | Citigroup | $15 → $10 | Maintains | Buy |
| 05/17/2022 | 1097.6% | Raymond James | $24 → $10 | Maintains | Outperform |
| 03/08/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 03/04/2022 | 2774.25% | Raymond James | $29 → $24 | Maintains | Outperform |
| 01/19/2022 | 618.56% | Goldman Sachs | $29 → $6 | Downgrades | Buy → Neutral |
| 07/01/2021 | 3373.05% | Raymond James | → $29 | Initiates Coverage On | → Outperform |
| 06/15/2021 | 2894.01% | BTIG | → $25 | Initiates Coverage On | → Buy |
| 03/08/2021 | 5289.22% | Chardan Capital | $35.5 → $45 | Maintains | Buy |
| 03/04/2021 | 3492.81% | Goldman Sachs | $28 → $30 | Upgrades | Neutral → Buy |
| 02/04/2021 | 2894.01% | Guggenheim | → $25 | Initiates Coverage On | → Buy |
| 01/04/2021 | 4091.62% | JP Morgan | $25 → $35 | Upgrades | Neutral → Overweight |
| 12/11/2020 | 3253.29% | Citigroup | → $28 | Initiates Coverage On | → Neutral |
| 08/14/2020 | 2894.01% | JP Morgan | → $25 | Downgrades | Overweight → Neutral |
| 06/25/2020 | 3253.29% | Goldman Sachs | → $28 | Downgrades | Buy → Neutral |
| 05/11/2020 | 3792.22% | Chardan Capital | $30 → $32.5 | Maintains | Buy |
| 03/25/2020 | 3492.81% | Chardan Capital | → $30 | Initiates Coverage On | → Buy |
| 03/24/2020 | 3133.53% | Goldman Sachs | → $27 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/08/2023 | 977.84% | 查丹資本 | 11 美元 → 9 美元 | 維護 | 購買 |
| 05/12/2023 | 977.84% | 雷蒙德·詹姆 | 10 美元 → 9 美元 | 維護 | 跑贏大盤 |
| 2022 年 12 月 15 日 | 1217.37% | 查丹資本 | 18 美元 → 11 美元 | 維護 | 購買 |
| 11/11/2022 | 1217.37% | 古根海姆 | 13 美元 → 11 美元 | 維護 | 購買 |
| 11/11/2022 | 498.8% | 花旗集團 | 7 美元 → 5 美元 | 維護 | 購買 |
| 2022 年 8 月 11 日 | 858.08% | Canaccord Genu | → 8 美元 | 啓動覆蓋開啓 | → 購買 |
| 05/17/2022 | 1097.6% | 花旗集團 | 15 美元 → 10 美元 | 維護 | 購買 |
| 05/17/2022 | 1097.6% | 雷蒙德·詹姆 | 24 美元 → 10 美元 | 維護 | 跑贏大盤 |
| 03/08/2022 | — | 摩根大通 | 降級 | 超重 → 中性 | |
| 03/04/2022 | 2774.25% | 雷蒙德·詹姆 | 29 美元 → 24 美元 | 維護 | 跑贏大盤 |
| 2022 年 1 月 19 日 | 618.56% | 高盛 | 29 美元 → 6 美元 | 降級 | 買入 → 中性 |
| 07/01/2021 | 3373.05% | 雷蒙德·詹姆 | → 29 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 06/15/2021 | 2894.01% | BTIG | → 25 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 8 月 3 日 | 5289.22% | 查丹資本 | 35.5 美元 → 45 美元 | 維護 | 購買 |
| 2021 年 4 月 3 日 | 3492.81% | 高盛 | 28 美元 → 30 美元 | 升級 | 中性 → 買入 |
| 2021 年 4 月 2 日 | 2894.01% | 古根海姆 | → 25 美元 | 啓動覆蓋開啓 | → 購買 |
| 01/04/2021 | 4091.62% | 摩根大通 | 25 美元 → 35 美元 | 升級 | 中性 → 超重 |
| 2020 年 11 月 12 日 | 3253.29% | 花旗集團 | → 28 美元 | 啓動覆蓋開啓 | → 中立 |
| 2020 年 8 月 14 日 | 2894.01% | 摩根大通 | → 25 美元 | 降級 | 超重 → 中性 |
| 06/25/2020 | 3253.29% | 高盛 | → 28 美元 | 降級 | 買入 → 中性 |
| 05/11/2020 | 3792.22% | 查丹資本 | 30 美元 → 32.5 美元 | 維護 | 購買 |
| 2020 年 3 月 25 日 | 3492.81% | 查丹資本 | → 30 美元 | 啓動覆蓋開啓 | → 購買 |
| 2020 年 3 月 24 日 | 3133.53% | 高盛 | → 27 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Passage Bio (PASG)?
Passage Bio（PASG）的目標價格是多少？
The latest price target for Passage Bio (NASDAQ: PASG) was reported by Chardan Capital on August 8, 2023. The analyst firm set a price target for $9.00 expecting PASG to rise to within 12 months (a possible 977.84% upside). 6 analyst firms have reported ratings in the last year.
Chardan Capital於2023年8月8日公佈了Passage Bio（納斯達克股票代碼：PASG）的最新目標股價。這家分析公司將目標股價定爲9.00美元，預計PASG將在12個月內升至977.84％（可能上漲977.84％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Passage Bio (PASG)?
分析師對Passage Bio（PASG）的最新評級是多少？
The latest analyst rating for Passage Bio (NASDAQ: PASG) was provided by Chardan Capital, and Passage Bio maintained their buy rating.
Passage Bio（納斯達克股票代碼：PASG）的最新分析師評級由Chardan Capital提供，Passage Bio維持買入評級。
When is the next analyst rating going to be posted or updated for Passage Bio (PASG)?
Passage Bio（PASG）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Passage Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Passage Bio was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Passage Bio的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Passage Bio的最後一次評級是在2023年8月8日提交的，因此你應該預計下一個評級將在2024年8月8日左右公佈。
Is the Analyst Rating Passage Bio (PASG) correct?
分析師評級 Passage Bio (PASG) 正確嗎？
While ratings are subjective and will change, the latest Passage Bio (PASG) rating was a maintained with a price target of $11.00 to $9.00. The current price Passage Bio (PASG) is trading at is $0.84, which is out of the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的Passage Bio（PASG）評級維持不變，目標股價爲11.00美元至9.00美元。Passage Bio（PASG）目前的交易價格爲0.84美元，超出了分析師的預測區間。